Avaris AB develops new cell therapies for chronic infections, cancer and
inherited diseases until proof of concept in humans (Phase II). The company is
based on four technology platforms within cell and gene therapy. Research is
done in-house and in close collaboration with academy, while manufacturing and
clinical trials are done in collaboration with CROs. Avaris was founded in 2001
and is privately owned.
Members
Tags
|
Avaris ABHälsovägen 7, floor 7ESE-141 52, HuddingeSwedenPhone: +46 8 728 3896Fax: +46 8 779 40 61URL: Webpage |